In advanced NSCLC patients, increased AREG expression correlates with a poor response to therapy, and several studies have identified AREG as a biomarker for an efficient response to EGFR-targeted therapies [69–71]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.